Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ferrandina

Showing results (111-120 of 176) with videos related to

Pageof 18
Sort By:
Journal of Cancer Research and Clinical Oncology|February 11, 2023
Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter studyA Rosati, V Vargiu, C Certelli, et al.
Cancer Research|August 14, 1999
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancerV Masciullo, A Sgambato, C Pacilio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancerG Ferrandina, F O Ranelletti, L M Larocca, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|May 4, 2011
Early-stage cervical cancer: agreement between ultrasound and histopathological findings with regard to tumor size and extent of local diseaseA Gaurilcikas, D Vaitkiene, A Cizauskas, et al.
International Journal of Cancer|September 4, 1995
Methyl-p-hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: correlation with biological and clinico-pathological parametersF O Ranelletti, G Scambia, P Benedetti Panici, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2002
Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgeryG Ferrandina, F O Ranelletti, F Legge, et al.
International Journal of Cancer|April 15, 1994
Quercetin enhances transforming growth factor beta 1 secretion by human ovarian cancer cellsG Scambia, P B Panici, F O Ranelletti, et al.
Gynecologic Oncology|September 7, 2010
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgeryG Ferrandina, P A Margariti, D Smaniotto, et al.
Oncogene|November 3, 2015
Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinomaE Semprucci, P Tocci, R Cianfrocca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patientsD Lorusso, G Ferrandina, S Greggi, et al.
Pageof 18

Showing results (111-120 of 176) with videos related to

Sort By:
Pageof 18
Journal of Cancer Research and Clinical Oncology|February 11, 2023
Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter studyA Rosati, V Vargiu, C Certelli, et al.
Cancer Research|August 14, 1999
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancerV Masciullo, A Sgambato, C Pacilio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancerG Ferrandina, F O Ranelletti, L M Larocca, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|May 4, 2011
Early-stage cervical cancer: agreement between ultrasound and histopathological findings with regard to tumor size and extent of local diseaseA Gaurilcikas, D Vaitkiene, A Cizauskas, et al.
International Journal of Cancer|September 4, 1995
Methyl-p-hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: correlation with biological and clinico-pathological parametersF O Ranelletti, G Scambia, P Benedetti Panici, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2002
Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgeryG Ferrandina, F O Ranelletti, F Legge, et al.
International Journal of Cancer|April 15, 1994
Quercetin enhances transforming growth factor beta 1 secretion by human ovarian cancer cellsG Scambia, P B Panici, F O Ranelletti, et al.
Gynecologic Oncology|September 7, 2010
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgeryG Ferrandina, P A Margariti, D Smaniotto, et al.
Oncogene|November 3, 2015
Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinomaE Semprucci, P Tocci, R Cianfrocca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patientsD Lorusso, G Ferrandina, S Greggi, et al.
Pageof 18